Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Didanosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | ALB | P02768 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | TYMP | P19971 | 2/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.46 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Didanosine SCHEMBL16695883 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL16695888 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL16695885 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL1674335 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL5021456 | 1.00 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL7904473 | 0.98 | ALDH1A1 (0.95) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL887093 | 0.95 | ALDH1A1 (0.91) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL284944 | 0.95 | ALDH1A1 (0.91) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL2327408 | 0.92 | ALDH1A1 (0.85) | ALDH1A1LMNAALBMAPK1TDP1 | |
| Didanosine SCHEMBL7787270 | 0.92 | ALDH1A1 (0.84) | ALDH1A1LMNAALBMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 43421 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144879-A1 | ANTI-VIRAL AND HEPATIC-TARGETED DRUGS | AI-BIOPHARMA (FR) | 2026-05-28 | — | — | US | claimed |
| EP-4746907-A1 | METHOD OF TREATMENT OF HIV INFECTION WITH VACCINE | Gilead Sciences, Inc. (US) | 2026-05-27 | — | — | EP | claimed |
| WO-2026104544-A1 | EXO-VINYLENE CARBONATE COMPOUNDS AS PRECURSORS FOR ISOCYANATE-FREE URETHANE-TYPE POLYMERS | BASF SE (DE) | 2026-05-21 | — | — | WO | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4745170-A1 | METHOD FOR PREPARING A URETHANE GROUP-CONTAINING POLYMER | BASF SE (DE) | 2026-05-20 | — | — | EP | claimed |
| EP-4094767-B1 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | UNIV EMORY (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4745169-A1 | COMPOSITION USEFUL AS COATING, SEALANT OR ADHESIVE | BASF SE (DE) | 2026-05-20 | — | — | EP | claimed |
| US-20260124290-A1 | HIV Immunogens, Vaccines, and Methods Related Thereto | UNIV EMORY (US) | 2026-05-07 | — | — | US | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| WO-2026085583-A1 | MOLECULAR ASSAY FOR DETECTING HIV-1 DRUG-RESISTANT MUTATIONS | ST VINCENT'S HOSPITAL SYDNEY LIMITED (AU) | 2026-04-30 | — | — | WO | claimed |
| WO-1991018089-A1 | ASSOCIATION BETWEEN A HUMAN IMMUNODEFICIENCY VIRUS-RELATED RETROVIRUS AND SJOGREN'S SYNDROME | GARRY ROBERT F JR (US) | 1991-11-28 | — | — | WO | claimed |
| WO-1991013623-A1 | C-5 MONO-SUBSTITUTED BARBITURATES IN COMBINATION WITH THERAPEUTIC AGENTS AND USES THEREOF | MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) | 1991-09-19 | — | — | WO | claimed |
| WO-1991009605-A1 | TREATMENT OF HUMAN RETROVIRAL INFECTIONS WITH 2',3'-DIDEOXYINOSINE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1991-07-11 | — | — | WO | claimed |
| EP-0416011-A4 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | US COMMERCE (US) | 1991-05-22 | — | — | EP | claimed |
| EP-0416011-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1991-03-13 | — | — | EP | claimed |
| EP-0398230-A2 | Antiviral, highly water soluble, stable, crystalline salts of 2',3'-dideoxyinoside monohydrate, 2',3'-dideoxy-2',3'-didehydrothymidine monohydrate and 2',3'-dideoxy-2'-fluoroinosine hemihydrate | Bristol-Myers Squibb Company (US) | 1990-11-22 | — | — | EP | claimed |
| WO-1990011081-A1 | INHIBITION OF HIV USING SYNERGISTIC COMBINATIONS OF NUCLEOSIDE DERIVATIVES | ONCOGEN LIMITED PARTNERSHIP (US) | 1990-10-04 | — | — | WO | claimed |
| WO-1989011277-A2 | PORPHYRIN AND PHTHALOCYANINE ANTIVIRAL COMPOSITIONS | GEORGIA STATE UNIVERSITY FOUNDATION, INC. (US) | 1989-11-30 | — | — | WO | claimed |
| WO-1989011274-A1 | CHEMOTHERAPEUTIC COMPOSITION FOR AIDS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH (US) | 1989-11-30 | — | — | WO | claimed |
| WO-1987001284-A1 | INHIBITION OF IN VITRO INFECTIVITY AND CYTOPATHIC EFFECT OF HTLV-III/LAV BY 2',3'-DIDEOXYNOSINE, 2',3'-DIDEOXYGUANOSINE, OR 2',3'-DIDEOXYADENOSINE | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1987-03-12 | — | — | WO | claimed |